Revenue of 708 yuan in the first quarter, or from selling second-hand incubators?
Recently, Shouyao holdings announced its first quarterly report after listing. The report shows that the company's operating revenue in the first quarter was only 707.96 yuan, a year-on-year decrease of - 99.98%.
More ironically, in the group chat screenshot circulated on the social platform, a netizen signed related to Shouyao Holdings said that the revenue in the first quarter of 2022 came from the sale of a second-hand incubator. In response, the Board Secretary of Shouyao holdings replied that Zhongxin Jingwei said that it was currently verifying with the finance department, subject to the official news.
As a listed company, such a small operating income is surprising. However, a closer look at the company's announcement found that the company is a science and innovation board enterprise listed on March 23, mainly engaged in the research and development of small molecule innovative drugs. The research and development cycle of new drug projects is long and the capital investment is large.
At present, all products of the company are in the stage of clinical trial and preclinical research. No products have been listed and no product sales revenue has been generated.
As of the closing on April 28, Shouyao holdings closed at 17.97 yuan / share, down 3.65%. Compared with the issue price of 39.9 yuan / share, the share price fell 55% in the 25 trading days after listing.
small molecule drug R & D enterprise, the company has no products on the market
The first quarterly report of Shouyao holdings disclosed that the company realized an operating revenue of 707.96 yuan in the first quarter, a year-on-year decrease of - 99.98%; The net profit attributable to the listed company was -506623 million yuan.
on the same day, Shouyao holdings also released its 2021 annual report. Last year, the company achieved an operating revenue of 130325 million yuan, an increase of 85.67% year-on-year; The net loss was 145 million yuan, with a year-on-year decrease of 56.10%, and the basic earnings per share was -1.30 yuan
However, the poor performance of Shouyao holdings is not due to poor management. According to the company's annual report, the company is a pharmaceutical enterprise focusing on the R & D, production and commercialization of innovative drugs with independent intellectual property rights. The R & D pipeline covers non-small cell lung cancer, lymphoma, hepatocellular carcinoma, pancreatic cancer, thyroid cancer, ovarian cancer, leukemia and other key tumor indications, as well as other important disease fields such as type II diabetes.
Shouyao Holdings said in its annual report that the company's new drug project has a long R & D cycle and large capital investment. At present, all products of the company are in the stage of clinical trial and preclinical research. No products have been listed and no product sales revenue has been generated. At the same time, the R & D income generated by the company's early cooperative R & D is small, which can not cover the company's R & D and operation investment in the reporting period, resulting in the company's unprofitable and unrecovered losses.
During the reporting period, the company made steady progress in the clinical research of new drugs under research, with good cash flow, stable core team, continuous participation of outstanding talents, and no major adverse changes in its main business and core competitiveness.
Shouyao Holdings said that as a leading innovative drug enterprise in China, the company attaches great importance to product R & D, and its R & D investment has increased significantly year by year. Taking anti-tumor new drugs as the core direction, the company aims to achieve first in class or best in class drugs of the same kind. During the reporting period, the company continued to increase R & D investment, and the annual R & D investment reached 157 million yuan.
During the reporting period, the phase II and III clinical trials of the second generation ALK inhibitor sy-707, the phase I clinical trial of the third generation ALK inhibitor sy-3505 and the phase II clinical trial of BTK inhibitor sy-1530 were steadily and rapidly promoted. Among them, sy-3505 is the third-generation ALK kinase inhibitor, which still has a good inhibitory effect on the key ALK mutants resistant to the first and second-generation ALK inhibitors. It is the first domestic third-generation ALK inhibitor to enter the clinical trial stage. Since sy-707 is an ALK / FAK / Pyk2 / IGF1R multi-target kinase inhibitor, the company actively explores other potential indications of sy-707 other than non-small cell lung cancer. In October, 2021, the application for clinical trial of sy-707 combined with treprizumab and gemcitabine in the treatment of advanced pancreatic cancer and other solid tumors has been approved by the State Food and drug administration.
Kechuang board company's performance growth is bright
Although the science and innovation board allows qualified unprofitable enterprises to be listed, and there are many unprofitable enterprises in the board, from the data, the overall performance of the science and innovation board in 2021 is still very bright.
According to the data, as of April 28, the science and Innovation Board enterprises that have disclosed the annual report of 2021 have an average real net profit of 227 million yuan, with an average year-on-year performance growth rate of 42.23%.
The net profit is up to 10.7 billion yuan Semiconductor Manufacturing International Corporation(688981) said in the annual report that since the company was included in the list of entities in the United States, its production and operation have faced great challenges. In 2021, with the efforts of all employees, the production continuity of the company was basically stable, and orderly promoted the expansion of mature processes, steadily improved the advanced process business, exceeding the revenue target of 2021.
Xinjiang Daqo New Energy Co.Ltd(688303) 's net profit reached 5.7 billion yuan. In addition, the net profits of Zhejiang Orient Gene Biotech Co.Ltd(688298) , Shenzhen Transsion Holdings Co.Ltd(688036) , China Railway Signal & Communication Corporation Limited(688009) and other companies are more than 3 billion yuan.
entered the first quarterly report, many Sci-tech Innovation Board companies still showed strong profitability, and many leaders in subdivided industries took the lead in handing over bright transcripts
Polycrystalline silicon leader Xinjiang Daqo New Energy Co.Ltd(688303) achieved a revenue of 8.129 billion yuan in the first quarter, a year-on-year increase of 389%; The net profit attributable to the parent company was 4.312 billion yuan, a year-on-year increase of 641%. Benefiting from the strong rebound in the demand of the photovoltaic industry, the materials for monocrystalline silicon produced by the company accounted for more than 97% in the first quarter of 2022, and realized the batch sales of n-type high-purity silicon materials, which is at the leading level in the industry.
IDM mode power semiconductor leader China Resources Microelectronics Limited(688396) achieved an operating revenue of 2.514 billion yuan in the first quarter, a year-on-year increase of 23%, and the net profit attributable to the parent company was 619 million yuan, a year-on-year increase of 55%. At the same time, the gross profit margin increased by 5.04 percentage points year-on-year. After listing, the company continued to increase technological innovation. The annual report shows that the comprehensive performance of the second generation 650V SiC JBS independently developed by the company has reached the advanced level in the industry, and a variety of products have achieved fruitful research and development such as mass production.
The company's high growth logic remains unchanged, its fundamentals are stable and good, and continues to make progress in technological breakthroughs and domestic substitution, showing the investment value and growth value of the science and innovation board.
